- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06253221
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
April 3, 2024 updated by: Bristol-Myers Squibb
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adolescents (Age 12 Years to < 18 Years) With Symptomatic Obstructive Hypertrophic Cardiomyopathy
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Contact Backup
- Name: First line of the email MUST contain the NCT# and Site #.
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2145
- Not yet recruiting
- Local Institution - 0020
-
Contact:
- Site 0020
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Not yet recruiting
- Local Institution - 0042
-
Contact:
- Site 0042
-
Parkville, Victoria, Australia, 3052
- Withdrawn
- Local Institution - 0028
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2R7
- Not yet recruiting
- Local Institution - 0041
-
Contact:
- Site 0041
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Not yet recruiting
- Local Institution - 0046
-
Contact:
- Site 0046
-
-
-
-
-
Paris, France, 75015
- Not yet recruiting
- Local Institution - 0022
-
Contact:
- Site 0022
-
Pessac, France, 33604
- Not yet recruiting
- Local Institution - 0026
-
Contact:
- Site 0026
-
-
-
-
BE
-
Berlin, BE, Germany, 13353
- Not yet recruiting
- Local Institution - 0018
-
Contact:
- Site 0018
-
-
BY
-
Munich, BY, Germany, 80636
- Not yet recruiting
- Local Institution - 0006
-
Contact:
- Site 0006
-
-
-
-
D
-
Drimnagh, D, Ireland, D12 V443
- Not yet recruiting
- Local Institution - 0047
-
Contact:
- Site 0047
-
-
-
-
-
Napoli, Italy, 80131
- Not yet recruiting
- Local Institution - 0027
-
Contact:
- Site 0027
-
-
FI
-
Firenze, FI, Italy, 50100
- Not yet recruiting
- Local Institution - 0016
-
Contact:
- Site 0016
-
-
GE
-
Genova, GE, Italy, 16147
- Not yet recruiting
- Local Institution - 0051
-
Contact:
- Site 0051
-
-
-
-
-
A Coruna, Spain, 15009
- Active, not recruiting
- Local Institution - 0011
-
Madrid, Spain, 28041
- Active, not recruiting
- Local Institution - 0023
-
Madrid, Spain, 28046
- Not yet recruiting
- Local Institution - 0025
-
Contact:
- Site 0025
-
-
B
-
Barcelona, B, Spain, 8950
- Not yet recruiting
- Local Institution - 0014
-
Contact:
- Site 0014
-
-
GR
-
Granada, GR, Spain, 18014
- Active, not recruiting
- Local Institution - 0021
-
-
M
-
Madrid, M, Spain, 28007
- Not yet recruiting
- Local Institution - 0048
-
Contact:
- Site 0048
-
-
-
-
-
London, United Kingdom, WC1N 3JH
- Not yet recruiting
- Local Institution - 0007
-
Contact:
- Site 0007
-
-
BFS
-
Belfast, BFS, United Kingdom, BT12 6BA
- Not yet recruiting
- Local Institution - 0049
-
Contact:
- Site 0049
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Not yet recruiting
- Local Institution - 0017
-
Contact:
- Site 0017
-
-
Arizona
-
Phoenix, Arizona, United States, 85016-7710
- Not yet recruiting
- Local Institution - 0050
-
Contact:
- Site 0050
-
-
California
-
Los Angeles, California, United States, 90027-6062
- Not yet recruiting
- Local Institution - 0032
-
Contact:
- Site 0032
-
Los Angeles, California, United States, 90095-8344
- Not yet recruiting
- Local Institution - 0008
-
Contact:
- Site 0008
-
Oakland, California, United States, 94609
- Not yet recruiting
- Local Institution - 0004
-
Contact:
- Site 0004
-
Palo Alto, California, United States, 94304-1601
- Not yet recruiting
- Local Institution - 0033
-
Contact:
- Site 0033
-
San Diego, California, United States, 92123-4223
- Not yet recruiting
- Local Institution - 0044
-
Contact:
- Site 0044
-
-
Colorado
-
Aurora, Colorado, United States, 80045-7106
- Not yet recruiting
- Local Institution - 0038
-
Contact:
- Site 0038
-
-
Florida
-
Saint Petersburg, Florida, United States, 33701-4634
- Not yet recruiting
- Local Institution - 0031
-
Contact:
- Site 0031
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Not yet recruiting
- Local Institution - 0053
-
Contact:
- Site 0053
-
-
Illinois
-
Chicago, Illinois, United States, 60637-1447
- Not yet recruiting
- Local Institution - 0013
-
Contact:
- Site 0013
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202-5272
- Recruiting
- Riley Hospital for Children - Pediatric Cardiology
-
Contact:
- John Parent, Site 0009
- Phone Number: 317-908-4944
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115-5724
- Not yet recruiting
- Local Institution - 0043
-
Contact:
- Site 0043
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan - C.S. Mott Children's Hospital
-
Contact:
- Mark Russell, Site 0002
- Phone Number: 734-660-3431
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Not yet recruiting
- Local Institution - 0037
-
Contact:
- Site 0037
-
-
New Jersey
-
Morristown, New Jersey, United States, 07960-6083
- Not yet recruiting
- Local Institution - 0052
-
Contact:
- Site 0052
-
-
New York
-
Bronx, New York, United States, 10467-2403
- Not yet recruiting
- Local Institution - 0040
-
Contact:
- Site 0040
-
New Hyde Park, New York, United States, 11042
- Recruiting
- Cohen Children's Medical Center of New York
-
Contact:
- Jeffrey Gossett, Site 0010
- Phone Number: 516-601-7291
-
New York, New York, United States, 10029-6574
- Not yet recruiting
- Local Institution - 0024
-
Contact:
- Site 0024
-
New York, New York, United States, 10032-1559
- Not yet recruiting
- Local Institution - 0036
-
Contact:
- Site 0036
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Not yet recruiting
- Local Institution - 0015
-
Contact:
- Site 0015
-
Durham, North Carolina, United States, 27705
- Not yet recruiting
- Local Institution - 0039
-
Contact:
- Site 0039
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Not yet recruiting
- Local Institution - 0019
-
Contact:
- Site 0019
-
Cleveland, Ohio, United States, 44195-0001
- Not yet recruiting
- Local Institution - 0001
-
Contact:
- Site 0001
-
Columbus, Ohio, United States, 43205
- Not yet recruiting
- Local Institution - 0029
-
Contact:
- Site 0029
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-4319
- Not yet recruiting
- Local Institution - 0030
-
Contact:
- Site 0030
-
Pittsburgh, Pennsylvania, United States, 15224-1334
- Not yet recruiting
- Local Institution - 0005
-
Contact:
- Site 0005
-
-
Tennessee
-
Memphis, Tennessee, United States, 38104
- Not yet recruiting
- Local Institution - 0034
-
Contact:
- Site 0034
-
-
Texas
-
Austin, Texas, United States, 78712
- Not yet recruiting
- Local Institution - 0045
-
Contact:
- Site 0045
-
Houston, Texas, United States, 77030
- Not yet recruiting
- Local Institution - 0054
-
Contact:
- Site 0054
-
-
Utah
-
Salt Lake City, Utah, United States, 84113-1103
- Not yet recruiting
- Local Institution - 0003
-
Contact:
- Site 0003
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908-0816
- Not yet recruiting
- Local Institution - 0012
-
Contact:
- Site 0012
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792-0002
- Not yet recruiting
- Local Institution - 0035
-
Contact:
- Site 0035
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of HCM
- Presence of LVOT obstruction
- Presence of symptoms
Exclusion Criteria:
- Phenocopy diseases resulting in myocardial hypertrophy not related to sarcomere dysfunction
- Evidence of LVEF <50% in prior 6 months
- Planned escalation in HCM therapy or upcoming intervention (eg, major cardiac surgery, HCM medication dose increase)
Other protocol-defined Inclusion/Exclusion criteria apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mavacamten
Participants assigned to this arm will receive mavacamten from day 1 to end of treatment at week 56.
|
Specified dose on specified days
Other Names:
|
Experimental: Placebo
Participants assigned to this arm will receive mavacamten from week 28 to end of treatment at week 56.
|
Specified dose on specified days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in Valsalva left ventricular outflow tract (LVOT) (VLVOT) gradient
Time Frame: At Week 28
|
At Week 28
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in resting LVOT gradient
Time Frame: At Week 28
|
At Week 28
|
Change from baseline in post-exercise peak LVOT gradient
Time Frame: At Week 28
|
At Week 28
|
Change from baseline in maximal wall thickness
Time Frame: At Week 28
|
At Week 28
|
Change from baseline in ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e')
Time Frame: At Week 28
|
At Week 28
|
Proportion of participants achieving an increase from baseline to Week 28 in peak oxygen uptake test (pVO2)
Time Frame: From baseline up to Week 28
|
From baseline up to Week 28
|
Proportion of participants achieving a reduction from baseline to Week 28 in maximal LVOT gradient to < 30 mmHg
Time Frame: From baseline up to Week 28
|
From baseline up to Week 28
|
Proportion of participants with at least 1 class improvement in New York Heart Association (NYHA) class from baseline to Week 28
Time Frame: From baseline up to Week 28
|
From baseline up to Week 28
|
Proportion of participants with at least 1 grade improvement in mitral regurgitation at Week 28
Time Frame: From baseline up to Week 28
|
From baseline up to Week 28
|
Number of participants with treatment-emergent adverse events (TEAEs)
Time Frame: Up to Week 74
|
Up to Week 74
|
Number of participants with treatment-emergent serious adverse events (TESAEs)
Time Frame: Up to Week 74
|
Up to Week 74
|
Change from baseline in electrocardiogram (ECG) (QT interval)
Time Frame: At Week 28
|
At Week 28
|
Number of participants with left ventricular ejection fraction (LVEF) ≤ 30%
Time Frame: Up to Week 56
|
Up to Week 56
|
Number of participants with LVEF ≤ 50%
Time Frame: Up to Week 56
|
Up to Week 56
|
Trough observed plasma concentration (Ctrough)
Time Frame: Up to Week 56
|
Up to Week 56
|
Post-dose plasma concentration of mavacamten
Time Frame: Up to Week 56
|
Up to Week 56
|
Maximum observed concentration (Cmax)
Time Frame: Up to Week 56
|
Up to Week 56
|
Area under the concentration-time curve (AUC)
Time Frame: Up to Week 56
|
Up to Week 56
|
Proportion of participants who evaluate taste and swallowability as neutral or better using taste and swallowability scales
Time Frame: At Day 1 and Week 11
|
At Day 1 and Week 11
|
Change from baseline in the Hypertrophic Cardiomyopathy Symptom Questionnaire - Shortness of Breath (HCMSQ SoB) domain
Time Frame: At Week 28
|
At Week 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 29, 2024
Primary Completion (Estimated)
February 15, 2028
Study Completion (Estimated)
March 29, 2030
Study Registration Dates
First Submitted
February 2, 2024
First Submitted That Met QC Criteria
February 2, 2024
First Posted (Actual)
February 12, 2024
Study Record Updates
Last Update Posted (Actual)
April 4, 2024
Last Update Submitted That Met QC Criteria
April 3, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CV027-010
- 2023-505650-17-00 (Other Identifier: EU CTR)
- U1111-1290-1175 (Other Identifier: WHO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.
Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html
IPD Sharing Time Frame
See plan description
IPD Sharing Access Criteria
See plan description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiomyopathy, Hypertrophic
-
French Cardiology SocietyCompleted1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy | 2- Obstructive Hypertrophic Cardiomyopathy | 3- Non Obstructive Hypertrophic CardiomyopathyFrance
-
Montreal Heart InstituteCanadian Institutes of Health Research (CIHR)Enrolling by invitationCardiomyopathies | Hypertrophic Cardiomyopathy | Hypertrophic Obstructive Cardiomyopathy | Familial Hypertrophic CardiomyopathyCanada
-
University of Sao PauloCompletedNon-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyBrazil
-
Bristol-Myers SquibbActive, not recruitingHypertrophic Cardiomyopathy | Non-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyDenmark, United States, Belgium, Czechia, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
-
Yonsei UniversityCompletedFamilial Hypertrophic CardiomyopathyKorea, Republic of
-
Hangzhou Valgen Medtech Co., LtdNot yet recruitingObstructive Hypertrophic CardiomyopathyChina
-
China National Center for Cardiovascular DiseasesNot yet recruitingObstructive Hypertrophic Cardiomyopathy
-
Bristol-Myers SquibbNot yet recruitingObstructive Hypertrophic CardiomyopathyKorea, Republic of
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.RecruitingObstructive Hypertrophic CardiomyopathyChina
-
Xiang WeiRecruitingNonobstructive Hypertrophic CardiomyopathyChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States